Abstract: Involved is an isolated antigen binding protein, being capable of binding CCR8 derived from a primate animal. Further involved are a pharmaceutical composition comprising the antigen binding protein, and an application of the antigen binding protein and/or the pharmaceutical composition in the prevention and/or treatment of a tumor or a cancer.

Abstract: A voltage regulator having a multiple of main stages and at least one accelerated voltage regulator (AVR) bridge is provided. The main stages may respond to low frequency current transients and provide DC output voltage regulation. The AVR bridges are switched much faster than the main stages and respond to high frequency current transients without regulating the DC output voltage. The AVR bridge frequency response range can overlap with the main stage frequency response range, and the lowest frequency to which the AVR bridges respond may be set lower than the highest frequency to which the main stages respond.

Abstract: The disclosure relates to power modules that include elevated inductors with capacitors disposed under the inductors. In one aspect, a power module includes a first circuit board having a first surface and a second surface opposite the first surface. One or more inductors are mounted on the first surface. Each of the one or more inductors includes a top surface and a bottom surface opposite the top surface and that faces the first surface of the first circuit board. Each inductor is elevated above the first surface of the first circuit board such that at least a portion of the bottom surface of the inductor does not contact the first surface of the first circuit board. The first circuit board includes capacitors arranged in an area below the portion of the bottom surface of the inductor that does not contact the first surface of the first circuit board.

Abstract: A method, system, and computer program product for circuit design automation. The method identifies a set of circuit components for a proposed circuit design. A subset of circuit components is selected to generate an initial topology for the proposed circuit design. A set of subsequent topologies are iteratively generated by a heuristic search algorithm based on the subset of circuit components and the initial topology. A set of valid topologies of the set of subsequent topologies are determined by a circuit simulator based on the subset of circuit components and a set of connections within the set of subsequent topologies. The method generates the proposed circuit design from the set of valid topologies.

Abstract: This application provides a channel access indication method and device. The method includes: receiving, by a first communications device, a channel synchronization request sent by a second communications device, where the channel synchronization request is used to request the first communications device to send a synchronization frame to the second communications device, and a wake-up receiver is configured for the second communications device; and according to the channel synchronization request and a time at which the second communications device is woken up and that is learned by the first communications device based on preset signaling, sending, by the first communications device when a channel is idle, the synchronization frame to the woken-up second communications device, where the synchronization frame is used to instruct the woken-up second communications device to access the channel after receiving the synchronization frame.

Abstract: Provided are an antigen binding protein capable of binding to PD-1 and a fusion protein thereof, and corresponding preparation method therefor and the use thereof. The fusion protein is capable of targeting PD-1 and CD73.

Abstract: The present invention discloses an ROR1-targeted antibody or an antigen-binding fragment thereof, a preparation method therefor and use thereof, wherein the ROR1-targeted antibody or the antigen-binding fragment thereof comprises a VL and a VH; the VL comprises the following CDRs or mutations thereof: VL CDR1, VL CDR2 and VL CDR3 as set forth in SEQ ID NOs: 69, 78 and 84, respectively; the VH comprises the following CDRs or mutations thereof: VH CDR1, VH CDR2 and VH CDR3 as set forth in SEQ ID NOs: 12, 33 and 53, respectively. The antibody or the antigen-binding fragment thereof described above has good binding affinity to ROR1, has almost no cross-reactivity with ROR2, has a KD value comparable to that of the reference antibody in the prior art, has a significant endocytosis effect, and has an ADCC effect in tumor cells.

Abstract: Provided an isolated antigen binding protein having one or more of the following properties: a. capable of binding to both human CD73 and Cynomolgus monkey CD73; b. capable of inhibiting 5?ectonucleotidase activity of CD73; c. capable of mediating CD73 internalization; d. capable of promoting T cell proliferation; e. with a relatively stable concentration in serum; and f. capable of inhibiting tumor growth and/or tumor cell proliferation. In addition, provided a method for producing the isolated antigen binding protein as well as pharmaceutical uses of the isolated antigen binding protein in preventing, alleviating and/or treating tumor.

Abstract: The present invention discloses a 4-1BB-binding protein and use thereof. The 4-1BB-binding protein comprises a heavy chain variable region, wherein the heavy chain variable region comprises HCDR1, HCDR2 and HCDR3, wherein the HCDR1 comprises a sequence as set forth in SEQ ID NO: 15 or a variant 1 thereof, or SEQ ID NO: 16; the HCDR2 comprises a sequence selected from SEQ ID NO: 60 or a variant 2 thereof, and SEQ ID NO: 50 or a variant 4 thereof; the HCDR3 comprises a sequence as set forth in SEQ ID NO: 103 or a variant 3 thereof, SEQ ID NO: 333 or a variant 5 thereof, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 116, SEQ ID NO: 326, SEQ ID NO: 331, SEQ ID NO: 334 or SEQ ID NO: 96. The 4-1BB-binding protein of the present invention is a fully human antibody having the binding activity to human 4-1BB and cynomolgus monkey 4-1BB. Some 4-1BB-binding proteins are only half the size of conventional IgG antibodies; they can be well used for bispecific antibodies.

Abstract: Provided are a residence time determination method and apparatus, an edge computing device, and a storage medium. The method includes that: a player image that is collected by an image collection apparatus and includes a specified part of a game player is acquired, and the image collection apparatus is deployed in a game area; identification information of the game player is determined on the basis of the feature information of the specified part in the player image; and the residence time of the game player in the game area is determined on the basis of the identification information of the game player and the existence time of the feature information of the game player in the game image.

Abstract: Provided is an anti-PD-L1 antigen binding protein, capable of binding to primate-derived PD-L1 with a KD value of 1×10?8 M or less. The antigen binding protein can block the binding of PD-1 and CD80 to PD-L1, stimulate the secretion of cytokines in immune cells, and can inhibit tumor growth and/or tumor cell proliferation. Also provided is a fusion protein, comprising human TGFBRII or a fragment thereof and the antigen binding protein. Also provided is an application of the antigen binding protein and/or the fusion protein in the prevention and treatment of tumors or cancers.

Abstract: Provided are a scene detection method and apparatus, an electronic device and a computer storage medium. The method includes: own device running data and scene information collected by a collection device are acquired through an own first detection system component; the device running data and the scene information are made pulled to a cloud for the cloud to detect itself and the collection device; in a case of a detection exception of the cloud, an own first device state is detected according to the device running data, and a second device state of the collection device is detected based on the scene information; and in a case where both the first device state and the second device state are normal, a scene state is detected according to a present frame of scene image in the scene information and a locally stored configuration file to obtain a detection result for use.

Abstract: The embodiments of the disclosure provide a game state detection and configuration updating method and apparatus, a device and a storage medium. The method includes that: description information of multiple configuration files of a first game table is acquired from a cloud; first description information is determined from the description information of the multiple configuration files, the version of a first configuration file described by the first description information being higher than that of a first local configuration file of the corresponding first game table; the first configuration file is acquired from the cloud to update the first local configuration file; and a game state of the first game table is detected according to the updated first local configuration file, as well as a first image collected for the first game table. The disclosure improves the accuracy of game state detection and the efficiency of configuration updating.

Abstract: In one embodiment, a method includes presenting a text message comprising n-grams via a user interface of a client system based on a user utterance received at the client system, receiving a first user request at the client system to edit the text message, presenting the text message visually divided into blocks via the user interface, wherein each block comprises one or more of the n-grams of the text message and the n-grams in each block are contiguous with respect to each other and grouped within the block based on an analysis of the text message by a natural-language understanding (NLU) module, receiving a second user request at the client system to edit one or more of the blocks, and presenting an edited text message generated based on the second user request via the user interface.

Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.

Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.

Abstract: Disclosed are isolated monoclonal antibodies, comprising a CD152-binding domain, wherein the antibodies bind specifically to human CD152. Methods of making and using the antibodies to treat diseases including cancers and autoimmune diseases are also provided.